Oncology Data Advisor™ · HRAS Mutations in Breast Cancer: Sam Kareff, MD, MPH Large population next-generation sequencing of tumors for mutations in certain key oncogenes is an important avenue of research for discovering genes that can predict survival or even support the use of targeted therapies for certain patients. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Sam Kareff, MD, MPH, presented a poster about his research about how mutations in the oncogene HRAS affect prognosis and response to therapy in breast cancer. He determined that certain types of HRAS mutation are associated with poor survival and that patients with these mutations may benefit from targeted therapies. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Nick Dionne-Odom, PhD, RN, Assistant Professor in the University of Alabama at Birmingham School of Nursing and School of Geriatric and Palliative Care, presented a poster about his clinical trial exploring cancer-related decisions and the health care team bias experienced by caregivers regarding these decisions. Afterwards, he spoke with Oncology Data Advisor to shed further light on the trial's results.  

Oncology Data Advisor™ · Medical Student Readiness to Treat LGBTQIA+ Patients: Matthew Schabath, PhD At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Matt Schabath, Associate Researcher at Moffitt Cancer Center, met with Oncology Data Advisor to discuss medical student readiness and confidence when treatin...

Oncology Data Advisor™ · Ocular Melanoma and Patient Advocacy: Danet Peterson At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Danet Peterson sat down with Oncology Data Advisor to talk about her work with A Cure in Sight, a nonprofit organization which seeks to support patients with ocular melanoma throughout the diagnosis, treatment, and survivorship journey. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Debra Patt, MD, PhD, MBA, FASCO, Executive Vice President of Texas Oncology and Clinical Professor at Dell Medical School at the University of Texas at Austin, presented her research regarding digital health solutions. Afterwards, she spoke with Oncology Data Advisor to further elucidate on the implications of digital health care for oncology practice. 

Oncology Data Advisor™ · Importance of Oncology State Societies: Stephanie Van Winkle. At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Ms. Stephanie Van Winkle, Executive Director of the Oncology State Societies at the Association for Community Cancer Centers (ACCC), sat down with Oncology Data Advisor to discuss how the oncology state societies and the Association for Community Cancer Centers empower legislative advocacy work.  This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.

Oncology Data Advisor™ · The Nurse's Role in Oncology Research and Quality Care: Jeannine Brant, PhD, APRN At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Jeannine Brant, PhD, APRN, President of the Oncology Nursing Society (ONS), sat down with Oncology Data Advisor to talk about the exciting resea...

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Beth Koselke, PharmD, BCOP, of the US Oncology Network, presented her team's research regarding the impact of a clinical pharmacist intervention program in oncology trial enrollment. Afterwards, she spoke with Oncology Data Advisor to explain the significance of t...

Oncology Data Advisor™ · Project Koru and Cancer Survivorship: Beth Peck Project Koru is a nonprofit organization that seeks to enrich the lives of young adult cancer survivors through outdoor and adventure-based community experiences. At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Beth Peck, the organization's Executive Director, sat down with Oncology Data Advisor to talk about its mission and the excitement of sharing the ASCO experience with others who have a common goal.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 

Oncology Data Advisor™ · Transforming Cancer Care Delivery and Patient Experiences Through Technology: David Penberthy, MD At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. David Penberthy, President of the Association of Community Cancer Centers (ACCC), sat down with Oncology Data Advisor to discuss his President's Theme for ACCC this year, which involves utilizing technology to improve the delivery of cancer care in order to optimize patient experiences. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 

Oncology Data Advisor™ · Pathology and Personalized Medicine: Aamir Ehsan, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Aamir Ehsan, MD, Medical Director at CorePath Laboratories, spoke with Oncology Data Advisor to delve into the topic of personalized and precise diagnosis of cancer by pathology, a topic that he is passionate about other pathologists and oncologists understanding.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago, by Oncology Data Advisor and ConveyMed. 

Oncology Data Advisor™ · Discussing Patient-Reported Hope in Early Phase Clinical Trials With Debra Lundquist, PhD, RN At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Debra Lundquist, PhD, RN, of Massachusetts General Hospital and colleagues presented their poster that sought to bridge the gap between recent advances in individual therapy which led to improved outcomes and a better understanding of patient-reported hope, quality of life, symptom burden, and coping mechanisms in early phase clinical trial participants. 

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Melissa Hudson of St. Jude Research Hospital, spoke with Oncology Data Advisor about the phase II trial of dabrafenib/trametinib for BRAF V600–mutant pediatric low-grade glioma, which was presented at the meeting by Dr. Eric Bouffet of the University...

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Ash Alpert, a postdoctoral fellow in health services research at Brown University, presented two posters regarding the associations between violence and cancer risk factors for transgender and cisgender people. In this follow-up interview with Oncology Data Advisor, Dr. Alpert delves further into the implications of these two studies' results and shares how their ongoing research in this field seeks to improve the care of transgender people in the health care setting.  

At the recent Oncology Nursing Society (ONS) Congress in Anaheim, California, Charles B. Simone, II, MD, FACRO, explained the concepts underlying the treatment of cancer with radiation therapy. In this interview with Oncology Data Advisor, Dr. Simone discusses the different types of radiation treatments and some considerations in choosing treatment. He also shares current evidence from his research about synergy between radiation therapy and checkpoint inhibitors or chemotherapy. 

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Debra Lundquist, PhD, RN, of Massachusetts General Hospital and colleagues presented their poster that sought to bridge the gap between recent advances in individual therapy which led to improved outcomes and a better understanding of patient-reported hope, quality of life, symptom burden, and coping mechanisms in early phase clinical trial participants.  

Oncology Data Advisor™ · Addressing Racial Disparities in Multiple Myeloma Treatment Outcomes Research has shown that Black American patients with multiple myeloma experience significant disparities in treatment patterns and outcomes compared with White patients. In this interview, Oncology Data Advisor editorial board member Dr. Rahul...

Cemiplimab, a programmed cell death protein 1 (PD-1) inhibitor, was approved in 2021 as the first and only systemic therapy to demonstrate clinical benefit among patients with advanced basal cell carcinoma (BCC) previously treated with hedgehog pathway inhibitor (HHI) therapy. At the American Association for Cancer Research (AACR) Annual Meeting in...

Oncology Data Advisor™ · From the Patient’s Perspective: Improving Quality of Care for the LGBTQIA+ Community At the recent 47th Annual Oncology Nursing Society (ONS) Congress, Reverend Sean Parker Dennison, alongside three other professionals, held a panel that explored the topic of improving quality of care for LGBTQIA+ individ...

Dr. Jochen Lorch, MD, MSc, is a Professor of Medicine and Medical Oncologist specializing in head, neck, and thyroid cancers at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. Dr. Lorch discusses the challenges of selecting treatment for advanced thyroid cancers, the importance of molecular testing for selection of kinase inhibitors in thyroid cancers, and future directions of research in thyroid cancer treatment selection and sequencing.